Skip to main content

Table 4 Adverse events reported in the included RCTs

From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review

Adverse events Studies reporting (n) MMF (n/n) Control (n/n) RR (95% CI) P value
Total patients with adverse events 7 27/148 20/125 1.14 [0.67, 1.93] 0.63
Specific adverse events      
Infection      
MMF vs Placebo (or Steroid) 3 5/72 0/64 3.84 [0.61, 24.03] 0.15
MMF vs other immunosuppressive agents 2 4/61 5/60 0.77 [0.22, 2.71] 0.68
Gastrointestinal disorders      
MMF vs Placebo (or Steroid) 3 7/72 0/64 5.02 [0.83, 30.15] 0.08
MMF vs other immunosuppressive agents 3 2/81 8/80 0.25 [0.05, 1.13] 0.07
Abnormal liver function      
MMF vs Placebo (or Steroid) 0 0 0 - -
MMF vs other immunosuppressive agents 4 4/102 6/90 0.66 [0.18, 2.42] 0.74
Abnormal blood counts      
MMF vs Placebo (or Steroid) 2 4/41 0/33 4.25 [0.46, 39.30] 0.20
MMF vs other immunosuppressive agents 3 3/82 5/70 0.53 [0.15, 1.94] 0.34
Hair loss      
MMF vs Placebo (or Steroid) 0 0 0 - -
MMF vs other immunosuppressive agents 2 0/61 2/60 0.32 [0.03, 3.02] 0.32
Irregular menstruation      
MMF vs Placebo (or Steroid) 0 0 0 - -
MMF vs other immunosuppressive agents 1 0/19 2/18 0.19 [0.01, 3.71] 0.27